Tareq Abadl: What Happens If You Transfuse the Wrong Blood Group?
Tareq Abadl, Medical Lab Specialist, shared a post on LinkedIn:
“What Happens If You Transfuse the Wrong Blood Group?
Imagine a patient urgently needs blood.
The transfusion starts, but the blood unit is incompatible with the patient’s blood group.
What happens next?
The patient’s immune system immediately recognizes the donor red blood cells as foreign.
Naturally occurring antibodies bind to the incompatible cells and trigger their destruction inside the bloodstream.
This can result in an Acute Hemolytic Transfusion Reaction (AHTR) — one of the most serious complications in transfusion medicine.
Signs and symptoms may include:
- Fever and chills
- Severe back or chest pain
- Shortness of breath
- Dark or red-colored urine
- Low blood pressure
- Acute kidney injury
In severe cases, the reaction can progress to shock, disseminated intravascular coagulation (DIC), multiple organ failure, and even death.
This is why blood bank professionals never rely on blood group labels alone.
Before a blood unit reaches a patient, several critical steps are performed:
- ABO and Rh typing
- Antibody screening
- Crossmatching
- Strict patient identification procedures.”

Other posts featuring Tareq Abadl on Hemostasis Today.
-
Sep 13, 2026, 16:09Dimitrios Syrengelas: Haemophilia Care Begins With Safe Movement
-
Sep 13, 2026, 15:33Christina (Tina) P.: Antiphospholipid Syndrome After Unprovoked VTE
-
Sep 13, 2026, 15:22Ioana Alexandra Voda: The Story Gets More Time at IFOS Istanbul
-
Sep 13, 2026, 14:52Omar Al Hammadi: Integrating Diabetes and Dyslipidemia in Modern Clinical Care
-
Sep 13, 2026, 14:37Mohammad Zamrood Khan: Hereditary Spherocytosis and Protein C/S Deficiency Case Report Submitted
-
Sep 13, 2026, 14:33Heghine Khachatryan: A Resource-Adapted Approach to Hemophilia Joint Care
-
Sep 13, 2026, 14:23Simon Fletcher: The Unmet Burden of Factor VII Deficiency
-
Sep 13, 2026, 14:10Azusa Nagao: The Evolving Burden of Haemophilia Prophylaxis
-
Sep 13, 2026, 13:50Priya Sriskandarajah: The Challenge of Thrombotic Risk in Myeloproliferative Neoplasms